Advancing research into the understanding and development of therapeutics for CDKL5 deficiency disorder

About the Loulou Foundation

Loulou Foundation is a private non-profit UK foundation dedicated to advancing research and development of therapeutics for CDKL5 Deficiency Disorder (CDD), a rare neurodevelopmental condition that affects tens of thousands of families worldwide. Since its establishment in 2015, the Foundation has funded important research projects at world-leading universities and research organizations, with a total of over 100 separate projects in more than 60 labs on four continents, enabling the focused research of greater than 200 scientists. Every year since 2015, the Foundation has hosted the CDKL5 Forum, an annual international symposium dedicated to CDKL5 and CDD. The CDKL5 Forum has become the preeminent scientific meeting dedicated to CDKL5, with nearly 200 scientists, clinicians, pharma industry representatives, and regulatory experts attending the most recent CDKL5 Forum. On October 27-28, 2025, the CDKL5 Forum will be held in Boston, USA, for two days of meetings covering basic science, translational and clinical development, and therapeutics updates on CDD. The Foundation has also launched an online portal to enable enhanced communication and collaboration by CDKL5 researchers: www.cdkl5forum.org.

A member of:

IRDIRC Rare Foundation Alliance Train CDKL5 Alliance Member
Download Brochure

Watch Video

News


Loulou Foundation

Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deficiency Disorder

5 May 2026

Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 Deficiency Disorder (CDD). Elaaj Bio is a wholly owned subsidiary of the Loulou Foundation, a private non-profit foundation dedicated to the development and research of therapeutics for CDD. The collaboration, to advance an investigational CDKL5 gene therapy, brings together complementary expertise across development and manufacturing services for adeno-associated virus (AAV) vectors to support advancement of the program toward clinical development.

Read More >>